Mesoblast Announces RYONCIL Net Sales of $30.3M for March 2026 Quarter

Mesoblast Limited (Nasdaq: MESO) announced preliminary net sales for RYONCIL (remestemcel-L-rknd) of US$30.3 million for the quarter ended March 31, 2026. This performance reflects strong growth in February and March, successfully offsetting seasonal trends observed in January. Total net revenue since the product's launch is approaching US$100 million. RYONCIL is currently the first and only FDA-approved mesenchymal stromal cell (MSC) therapy for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD). The company highlighted that these revenues strengthen its balance sheet and support ongoing label expansion efforts into adult SR-aGvHD and biologic-resistant inflammatory bowel disease. Additionally, Mesoblast is advancing its late-stage pipeline, including rexlemestrocel-L for heart failure and chronic low back pain. The company plans to detail its growth strategy and product pipeline during its inaugural R&D Day on April 8, 2026.